John L Beyer1, Kim G Johnson2. 1. Duke University Medical Center, Durham, NC, USA. 2. Duke University Medical Center, Durham, NC, USA. kim.g.johnson@duke.edu.
Abstract
This paper reviews recent research on late-life depression (LLD) pharmacotherapy, focusing on updated information for monotherapy and augmentation treatments. We then review new research on moderators of clinical response and how to use the information for improved efficacy. RECENT FINDINGS: A recent review shows that sertraline, paroxetine, and duloxetine were superior to placebo for the treatment of LLD. There is concern that paroxetine could have adverse outcomes in the geriatric population due to anticholinergic properties; however, studies show no increases in mortality, dementia risk, or cognitive measures. Among newer antidepressants, vortioxetine has demonstrated efficacy in LLD, quetiapine has demonstrated efficacy especially for patients with sleep disturbances, and aripiprazole augmentation for treatment resistance in LLD was found to be safe and effective. Researchers have also been identifying moderators of LLD that can guide treatment. Researchers are learning how to associate moderators, neuroanatomical models, and antidepressant response. SSRI/SNRIs remain first-line treatment for LLD. Aripiprazole is an effective and safe augmentation for treatment resistance. Studies are identifying actionable moderators that can increase treatment response.
This paper reviews recent research on late-life depression (LLD) pharmacotherapy, focusing on updated information for monotherapy and augmentation treatments. We then review new research on moderators of clinical response and how to use the information for improved efficacy. RECENT FINDINGS: A recent review shows that sertraline, paroxetine, and duloxetine were superior to placebo for the treatment of LLD. There is concern that paroxetine could have adverse outcomes in the geriatric population due to anticholinergic properties; however, studies show no increases in mortality, dementia risk, or cognitive measures. Among newer antidepressants, vortioxetine has demonstrated efficacy in LLD, quetiapine has demonstrated efficacy especially for patients with sleep disturbances, and aripiprazole augmentation for treatment resistance in LLD was found to be safe and effective. Researchers have also been identifying moderators of LLD that can guide treatment. Researchers are learning how to associate moderators, neuroanatomical models, and antidepressant response. SSRI/SNRIs remain first-line treatment for LLD. Aripiprazole is an effective and safe augmentation for treatment resistance. Studies are identifying actionable moderators that can increase treatment response.
Authors: Mark D Miller; Ellen Frank; Cleon Cornes; Patricia R Houck; Charles F Reynolds Journal: Am J Geriatr Psychiatry Date: 2003 Jan-Feb Impact factor: 4.105
Authors: Philip S Wang; Sebastian Schneeweiss; M Alan Brookhart; Robert J Glynn; Helen Mogun; Amanda R Patrick; Jerry Avorn Journal: J Clin Psychopharmacol Date: 2005-04 Impact factor: 3.153
Authors: Sarah Shizuko Morimoto; Faith M Gunning; Dora Kanellopoulos; Christopher F Murphy; Sibel A Klimstra; Robert E Kelly; George S Alexopoulos Journal: Int J Geriatr Psychiatry Date: 2011-05-25 Impact factor: 3.485
Authors: Michael Robinson; Tina Myers Oakes; Joel Raskin; Peng Liu; Scarlett Shoemaker; J Craig Nelson Journal: Am J Geriatr Psychiatry Date: 2013-02-06 Impact factor: 4.105
Authors: Eric J Lenze; Elizabeth R Skidmore; Amy E Begley; John W Newcomer; Meryl A Butters; Ellen M Whyte Journal: Int J Geriatr Psychiatry Date: 2011-12-16 Impact factor: 3.485
Authors: Jürgen Unützer; Michael Schoenbaum; Wayne J Katon; Ming-Yu Fan; Harold A Pincus; Diane Hogan; Jennifer Taylor Journal: J Am Geriatr Soc Date: 2009-01-16 Impact factor: 5.562
Authors: S Greten; J I Müller-Funogea; O Krause; M Klietz; F Wegner; G U Höglinger; N Simon; U Junius-Walker; S Gerbel Journal: J Neural Transm (Vienna) Date: 2020-12-01 Impact factor: 3.575
Authors: Sanne Wassink-Vossen; Richard C Oude Voshaar; Paul Naarding; Rose M Collard Journal: Int J Ment Health Nurs Date: 2022-02-09 Impact factor: 5.100
Authors: Shawn M McClintock; Lex Minto; David A Denney; K Chase Bailey; C Munro Cullum; Vonetta M Dotson Journal: Curr Psychiatry Rep Date: 2021-07-13 Impact factor: 8.081